FDA Approves New Drug for Depression Called Esketamine; Chemical Cousin to Illegal Club Drug “Special K”, Otherwise Known as Ketamine
To comply with FTC regulations, all links on this site could lead to commissions paid to the publisher. Please see Advertising Disclosure in sidebar.
NEW YORK – The Food and Drug Administration (FDA) approved esketamine nasal spray Tuesday to treat people with depression who have not found relief with traditional antidepressants.
“There has been a long-standing need for additional effective treatments for treatment-resistant depression, a serious and life-threatening condition,” Dr. Tiffany Farchione of the FDA’s Center for Drug Evaluation and Research said in a statement.
The drug will be manufactured by Janssen, a subsidiary of Johnson & Johnson, and sold as Spravato, reported BBC. Janssen said the spray can help adults dealing with depression and suicidal thoughts within 24 hours. The drug works by targeting glutamate, a chemical that is essential for normal brain function.
Patients cannot administer the spray at home. They must be supervised at a doctor’s office or clinic for two hours every time they take Spravato because of its side effects including dissociation, suicidal thoughts and a sense of detachment from one’s identity, according to the FDA.
Spravato is intended to be taken alongside an oral antidepressants, reported BBC.
Big Tech is censoring our publication severely reducing our traffic and revenue. (How they do it: NewsGuard) You can support our mission of truthful reporting by making a contribution. We refuse to let Silicon Valley crush us into becoming just another regurgitated, propaganda driven, echo-chamber of traditional news media and we need your support. You can also help by signing up for our featured story emails.
The esketamine nasal spray’s wholesale price per treatment will be between $590 and $885, Johnson & Johnson said according to NPR. Jennifer Taubert, worldwide chairwoman of pharmaceuticals for Johnson & Johnson, was one of seven pharmaceutical company executives who testified at a Senate Finance Committee hearing on drug prices on Feb. 26.
Some experts maintain esketamine is not ready to hit the market.
“The threshold has been two adequate and well-controlled trials. In this case, they only got one,” Dr. Erick Turner, a former FDA reviewer and professor at Oregon Health and Science University, said according to BBC.
An FDA advisory panel made waves when it approved esketamine for depression in February.